

**TAMARA A. SEYMOUR**

Interim Chief Financial Officer



Tamara A. Seymour, M.B.A., joined Immunic in April 2019, bringing with her more than three decades of corporate finance experience in the biotech and life sciences industries.

Since 2018, Ms. Seymour has served as a financial advisor, assisting life sciences companies with merger and acquisition activities and other finance-related needs. From 2014 to 2017, she served as Chief Financial Officer of Signal Genetics Inc. (now miRagen Therapeutics, Inc.), a publicly traded commercial-stage, molecular genetic diagnostics company focused on multiple myeloma. From 2010 to 2014, Ms. Seymour served as Chief Financial Officer of Hemaquest Pharmaceuticals, Inc., a venture-backed clinical development stage biotechnology company developing proprietary small molecules for the treatment of life-threatening hematologic disorders. From 2001 to 2009, Ms. Seymour served as Chief Financial Officer of Favril, Inc. (now MMR Global, Inc.), a publicly traded clinical development stage biopharmaceutical company developing therapeutic vaccines for non-Hodgkin's lymphoma. While at Favril, she was instrumental in raising more than 200 million USD in multiple private and public equity and debt financings, including the company's IPO. Earlier in her career, Ms. Seymour consulted as Chief Financial Officer for a number of biotechnology companies and served for more than eight years in various positions, including audit manager, with Deloitte LLP and PricewaterhouseCoopers LLP. She is currently a member of the board of directors and audit committee chair of Beacon Discovery, Inc., a privately-held company working to identify and advance molecules targeting G protein-coupled receptors.

Ms. Seymour, a certified public accountant (inactive), received an M.B.A., with an emphasis in finance, from Georgia State University and earned her B.B.A., with an emphasis in accounting, from Valdosta State University.

**PROFILE**
**Skills**

Expertise in equity and debt financing instruments for private and publicly-traded companies and developing infrastructure necessary for companies to transition from private to publicly-traded

**Qualification**

M.B.A. in finance and B.B.A. in accounting, C.P.A. (inactive)

**Experience**

More than 30 years of financial management experience in the life sciences industry

**Motivation**

Provide new therapies for patients suffering with debilitating diseases